EU cancer rates+predictions for 2025 Annals of Oncology: - WHO analysis from 5 largest countries🇪🇺+UK -⬇️incidence of all cancers, except pancreatic cancer, females with bladder & LC* - LC accounts for ⬆️est cancer mortality of men&women OncoAlert #LCSM annalsofoncology.org/article/S0923-…

👉#ELCC25: Subcutaneous pembrolizumab demonstrates noninferiority to intravenous administration in the phase III MK-3475A-D77 #ClinicalTrial in #NSCLC. Results plus commentary in the #ESMODailyReporter 🔗 ow.ly/6IOH50VpNRR

KROCUS study by Dr. Margarita Majem Phase 2 of 1L fulzerasib + cetuximab in KRAS G12C NSCLC 🔹 confirmed ORR 68.9% 🔹 +CNS activity 🔹 mPFS 12.5 mo #ELCC25 #LCSM #LungCancer KRASKickers

q6 subcut pembro is non-inferior to q6 intravenous I suspect this will be practice changing 🚨2ml infusion over 4mins Important impact for SACT services worldwide and better patient experience #ELCC2025

Ph2 COCOON trial: Primary derm prophylaxis vs. Reactive derm treatment of AEs for patients on Amivantimab for EGFR mutant NSCLC 50% reduction in Gr2 derm AEs 8% decrease in DR from AEs Underlines importance of primary preventative derm therapies to improve QoL #ELCC2025

sacituzumab govitecan (SG) vs sacituzumab tirumotecan (Sac-TMT) = antibody ≈ DAR (7.6 vs 7.4) ≠ conjugation chemistry (maleimide vs pyrimidine) ≈ linker (except conjugation part) = carbonate cleavable group ≠ payload structure and properties (SN-38 vs KL610023)

Back to back Nature Medicine papers! sac-TMT in previously treated, advanced NSCLC (SKB264-II-08 phase 2): nature.com/articles/s4159… sac-TMT versus chemotherapy in patients with locally recurrent or metastatic TNBC (OptiTROP-Breast01 phase 3): nature.com/articles/s4159…

Looking forward to contributing to this roundtable event discussing equitable healthcare in oncology. This is such an important topic that needs to be top of the agenda in oncology care

Short-term hybrid prehabilitation for resectable NSCLC improves patient functional and #PROs particularly among women and those from more deprived areas Great work at Barts Thorax Centre Will Ricketts 💙💛💙 🕊️ Jordan Curry, PhD Dr Adam Januszewski & the amazing Alice Finch academic.oup.com/icvts/article/…

Several agents are in development for both EGFR exon 20 insertion and HER2-mutant NSCLC. Gathering data on the impact of specific prior therapies in predicting response will be critical for informing treatment sequencing strategies. #ASCO25

SACHI: Savolotinib+Osimertinib in METamp EGFRmut post Osi 👉METamp by FISH 👉1K screened, 200 random’d mPFS ✅ ITT 8.2 v 4.5m (ITT) ✅ post 3rd gen TKI 6.9m v 3.0 HR 0.32 Benefit maintained in CNS mets No diff OS, Xover allowed Global Ph3 SAVANNAH ongoing #LCSM #ASCO25

🚨Sac-TMT vs. docetaxel in metastatic EGFRmut Lung cancer. RR: 45% vs 15% OS: NR with HR 0.49 PFS: 6.9 vs 2.8 months HR 0.30 Great data. We are fortunate to have MK2870 trial for 3rd line oncogenic driven lung Ca Barts Cancer Centre - good option for patients in UK!

More patients cured with neoadjuvant immunotherapy: CheckMate-816 OS now in #NEJM #ASCO2025

‘If this was a HR of a drug intervention you would get a standing ovation’ Fascinating data presented #ASCO25 on impact of timing of IO administration across the day (before vs. After 15:00)

‘We have probably seen the dial move further for extensive stage small cell lung cancer in the last 3hours than we have in the last 20 years’ 👏🏻 👏🏻👏🏻 #ASCO25

BTOG Welcomes New Trainees to the Steering Committee: Oncology Trainee Representative from July 2025 Dr Kishen Patel Clinical Research Fellow / Clinical Oncology Registrar University College London Dr Paolo Davide d'Arienzo CRUK Clinical Research Training Fellow, RAS lab, The

❗️Delighted to announce new partership between @BTOG & IASLC ❗️ If you are a BTOG member, you get 30% off IASLC membership Even more reason to be a member of both organisations 🤗

Join us for this The King's Fund online panel with S Woolnough Prof Sir M Richards CBE L Pero MBE Dr U Shukla Discussing what the NHS 10 year plan means for people living with cancer & how can ambition turn into action 16/Oct/25 @ 13:00-14:00 #KFOnline kingsfund.org.uk/events/deliver…

Real world outcomes with neoadjuvant osimertinib and/or chemotherapy in EGFR NSCLC Lung Cancer Journal from Dr. Jamie Chaft. Noted 17% pCR with osimertinib (none with chemotherapy), MPR 44% osimertinib, 0% chemo, 10% osimertinib + chemo. lungcancerjournal.info/article/S0169-…

Join me at this The King's Fund roundtable webinar with Q&A discussing the implications of the 10 year health plan for cancer care with Prof Sir Mike Richards Leanne Graham Dr Urmi Shukla Sarah Woolnough Starts at 13:00 today. Sign up here ⬇️ #KFOnline kingsfund.org.uk/events/deliver…